Tesamorelin in 2026: What the New Meta-Analysis Adds to the GHRH Picture
A meta-analysis published in Obesity Research & Clinical Practice in 2026 pooled five randomised controlled trials of tesamorelin. The selectivity story it tells — visceral and hepatic fat down, subcutaneous fat and BMI unchanged — is the clearest confirmation yet of what makes this GHRH analogue distinct.
- A 2026 meta-analysis in Obesity Research & Clinical Practice pooled five randomised controlled trials of tesamorelin versus placebo in adults with HIV-associated lipodystrophy.
- Pooled results: visceral fat, trunk and limb fat, hepatic fat percentage and waist circumference all fell, while lean body mass and IGF-1 rose.
- Subcutaneous fat and BMI did not change meaningfully — the depot selectivity that distinguishes tesamorelin from general weight-reduction compounds.
- CD4+ T-cell counts were unchanged and glucose was not perturbed; reported adverse effects were arthralgia and myalgia, paraesthesia, and injection-site reactions.
- Tesamorelin acts exclusively at the GHRH receptor, unlike ghrelin-receptor secretagogues such as ipamorelin, CJC-1295 or GHRP-6 — which is what makes it a clean tool for isolating the GHRH arm.
- Popular Peptides supplies tesamorelin (10 mg) for in vitro laboratory research use only — not approved by Health Canada for therapeutic use and not for human or veterinary consumption.
Why tesamorelin keeps its own lane
Most growth-hormone research compounds in a peptide catalogue act on the **ghrelin** receptor — ipamorelin, CJC-1295 combinations, GHRP-6. Tesamorelin does not. It is a synthetic analogue of growth hormone-releasing hormone, retaining the full 44-amino-acid human GHRH sequence with a trans-3-hexenoic acid group added at the N-terminus to resist proteolytic degradation, and it acts exclusively at the **GHRH receptor**.
That receptor selectivity is the whole research value. If a study needs to isolate the GHRH arm of the growth hormone axis without ghrelin-receptor confounding, tesamorelin is the tool that does it.
For the underlying mechanism, our earlier overview covers the pathway in detail: Tesamorelin: GHRH Analogue Research and Metabolic Applications. This post is about what has been added since.
The 2026 meta-analysis
Badran and colleagues published a systematic review and meta-analysis in **Obesity Research & Clinical Practice (2026)**, searching multiple databases through July 2025 and pooling **five randomised controlled trials** comparing tesamorelin against placebo in adults with HIV-associated lipodystrophy.
Pooling matters here. The individual tesamorelin trials — going back to the Falutz NEJM trial in 2007 — were each powered for their own endpoints, and a compound whose signature claim is *selectivity* is exactly the case where pooled data either confirms the pattern or dissolves it.
It confirmed it.
What moved, and what did not
Reduced:
- —Visceral adipose tissue
- —Trunk fat and limb fat
- —Hepatic fat percentage
- —Waist circumference
Increased:
- —Lean body mass
- —IGF-1
Not meaningfully changed:
- —Subcutaneous fat
- —BMI
That last pair is the finding worth sitting with. A compound that reduced visceral fat, raised lean mass, and left BMI essentially where it started is not producing generalised weight reduction — it is redistributing where fat is held. For research models of visceral adiposity specifically, that separation between depots is the property under study, and it is why tesamorelin is not interchangeable with metabolic compounds that move total mass.
**Safety signals reported:** CD4+ T-cell counts were unchanged and glucose was not perturbed — the latter being a standing question for any compound that raises GH and IGF-1. Reported adverse effects were arthralgia and myalgia, paraesthesia, and injection-site reactions.
The hepatic fat thread
The hepatic fat result is the one with the most forward momentum. Liver-fat reduction has been the most actively pursued extension of the tesamorelin literature, and having it hold up across pooled randomised data strengthens the case for GHRH-axis stimulation as a mechanistic lever on hepatic lipid handling — separate from, and additive to, the visceral-depot finding it was originally studied for.
How it differs from the ghrelin-receptor compounds
| Compound | Receptor | Research use |
|---|---|---|
| Tesamorelin | GHRH receptor | Isolating the GHRH arm; visceral and hepatic lipid models |
| [CJC-1295 (No DAC)](/products/cjc-1295-no-dac) | GHRH receptor (modified analogue) | GHRH-pathway work with a different half-life profile |
| [Ipamorelin](/products/ipamorelin) | Ghrelin receptor (GHS-R) | Selective GH secretagogue studies |
| [CJC-1295 + Ipamorelin](/products/cjc-ipamorelin) | Both | Combined-pathway models |
A side-by-side on the two GHRH-side compounds is in CJC-1295 vs Tesamorelin.
Reading this correctly
The trials pooled in this meta-analysis studied an approved medicine, administered under clinical protocol, in a specific patient population with HIV-associated lipodystrophy. None of it describes what happens outside that setting, and none of it is guidance.
Material supplied by Popular Peptides is research-grade tesamorelin for **in vitro laboratory work only**. It is not a medicine, is not sold for human or veterinary use, and research-use labelling does not confer any other legal status — a point Health Canada has stated directly.
Primary literature
- —Badran AS, Helal A, Shata KS, Ayesh H. *Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.* Obesity Research & Clinical Practice, 2026. doi:10.1016/j.orcp.2026.01.002
- —Falutz J, et al. *Metabolic effects of a growth hormone-releasing factor in patients with HIV.* New England Journal of Medicine, 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375
Sourcing these compounds in Canada
Compounds referenced in this guide:
- —**Tesamorelin** — 10 mg, GHRH analogue
- —**CJC-1295 (No DAC)**
- —**Ipamorelin** and **CJC-1295 + Ipamorelin**
These are supplied for laboratory research use and ship from within Canada — Vancouver, BC, typically 2 to 5 business days, tracked and insured. Published-batch HPLC purity averages above 99%, verified by a third-party lab, and every certificate is searchable by lot number. No customs risk, no USD conversion, free shipping over $300 CAD.
Frequently asked questions
What is new in tesamorelin research in 2026?
A meta-analysis published in Obesity Research & Clinical Practice pooled five randomised controlled trials and confirmed reductions in visceral fat, trunk and limb fat, hepatic fat percentage and waist circumference, with increases in lean body mass and IGF-1, and no meaningful change in subcutaneous fat or BMI.
How is tesamorelin different from ipamorelin or CJC-1295?
Tesamorelin acts at the GHRH receptor. Ipamorelin acts at the ghrelin receptor. CJC-1295 is also a GHRH-receptor analogue but with a different modification and half-life profile. The receptor difference is what makes tesamorelin useful for isolating the GHRH pathway.
Does tesamorelin affect subcutaneous fat?
In the pooled randomised data, no — subcutaneous fat and BMI did not change meaningfully, while visceral and hepatic fat did. That depot selectivity is the compound's defining research characteristic.
Is tesamorelin approved in Canada?
Tesamorelin is an approved prescription medicine in Canada for a specific indication, obtained through a physician and a pharmacy. That is entirely separate from research-grade material, which Popular Peptides supplies for in vitro laboratory use only and does not sell for human or veterinary use.
What purity is the research-grade material?
Published batches assay above 99% by HPLC with identity confirmed by LC-MS at an independent third-party laboratory. Every lot number is verifiable at /verify.
---
Tesamorelin is supplied for in vitro laboratory research use only. It is not approved by Health Canada for therapeutic use in the form supplied, is not a treatment for any condition as supplied, and is not intended for human or veterinary consumption. 18+.
Every batch we sell is independently third-party tested, with the full Certificate of Analysis published and checkable by lot number.